Helen Dakin
Research groups
Colleges
Helen Dakin
MSc DPhil
University Research Lecturer
Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
Recent publications
-
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial.
Becker F. et al, (2021), Diabetes Res Clin Pract
-
Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT.
Hopewell S. et al, (2021), Health Technol Assess, 25, 1 - 158
-
Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders (GRASP): a multicentre, pragmatic, 2x2 factorial randomised controlled trial
HOPEWELL S. et al, (2021), The Lancet
-
Progressive exercise versus best practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP 2x2 factorial RCT and economic evaluation
HOPEWELL S. et al, (2021), Health Technology Assessment
-
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
Dakin H. et al, (2020), Value in Health